haloperidol has been researched along with Impotence in 8 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Polydipsia was the most prevalent (24, 60." | 1.51 | Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. ( Chikowe, I; Domingo, M; Kampira, E; Mafuta, C; Mwakaswaya, V; Parveen, S, 2019) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| " New dopamine D4 receptor agonists, exemplified by (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (59a) and (E)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (64a), exhibited favorable pharmacokinetic profiles and showed oral bioavailability in rat and dog." | 1.33 | 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. ( Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM, 2006) |
| "The goal of this study was to identify a structurally distinct D(4)-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction." | 1.33 | Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ( Brioni, JD; Chang, R; Cowart, MD; Darbyshire, JF; Donnelly-Roberts, DL; El-Kouhen, OF; Gintant, G; Hakeem, AA; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martin, R; Martino, BR; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Nelson, SL; Patel, MV; Rohde, JJ; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME; Wetter, JM, 2006) |
| "The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents." | 1.31 | Sexual side effects of novel antipsychotic medications. ( Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enguehard-Gueiffier, C | 1 |
| Hübner, H | 1 |
| El Hakmaoui, A | 1 |
| Allouchi, H | 1 |
| Gmeiner, P | 1 |
| Argiolas, A | 1 |
| Melis, MR | 1 |
| Gueiffier, A | 1 |
| Kolasa, T | 2 |
| Matulenko, MA | 2 |
| Hakeem, AA | 2 |
| Patel, MV | 2 |
| Mortell, K | 2 |
| Bhatia, P | 1 |
| Henry, R | 1 |
| Nakane, M | 2 |
| Hsieh, GC | 2 |
| Terranova, MA | 2 |
| Uchic, ME | 2 |
| Miller, LN | 2 |
| Chang, R | 2 |
| Donnelly-Roberts, DL | 2 |
| Namovic, MT | 2 |
| Hollingsworth, PR | 2 |
| Martino, B | 1 |
| El Kouhen, O | 1 |
| Marsh, KC | 2 |
| Wetter, JM | 2 |
| Moreland, RB | 2 |
| Brioni, JD | 2 |
| Stewart, AO | 2 |
| Rohde, JJ | 1 |
| Nelson, SL | 1 |
| Cowart, MD | 1 |
| El-Kouhen, OF | 1 |
| Martino, BR | 1 |
| Martin, R | 1 |
| Darbyshire, JF | 1 |
| Gintant, G | 1 |
| Sullivan, JP | 1 |
| Chikowe, I | 1 |
| Domingo, M | 1 |
| Mwakaswaya, V | 1 |
| Parveen, S | 1 |
| Mafuta, C | 1 |
| Kampira, E | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Lare, SB | 1 |
| Labbate, LA | 1 |
| Wirshing, DA | 1 |
| Pierre, JM | 1 |
| Marder, SR | 1 |
| Saunders, CS | 1 |
| Wirshing, WC | 1 |
| Meco, G | 1 |
| Falaschi, P | 1 |
| Casacchia, M | 1 |
| Rocco, A | 1 |
| Petrini, P | 1 |
| Rosa, M | 1 |
| Agnoli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for haloperidol and Impotence
| Article | Year |
|---|---|
2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
Topics: Animals; Cattle; CHO Cells; Cricetinae; Cricetulus; Erectile Dysfunction; Guanosine 5'-O-(3-Thiotrip | 2006 |
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug | 2006 |
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Topics: Action Potentials; Administration, Oral; Animals; Benzamides; Biological Availability; Cell Line; Cy | 2006 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Sildenafil and erectile dysfunction.
Topics: Antipsychotic Agents; Erectile Dysfunction; Haloperidol; Humans; Male; Middle Aged; Phosphodiesteras | 2000 |
Sexual side effects of novel antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Clozapine; Erectile Dysfunction; Fluphenazine; Haloperidol; Humans; Mal | 2002 |
Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Drug Tolerance; Erectile Dysfunction; Female; Haloperidol; Human | 1985 |